2025年12月8日,三家企业几乎同时公布的临床结果,让减肥管线的技术版图在一天之内出现了罕见的多点扩展。Structure Therapeutics(硕迪)的口服小分子aleniglipron在2期试验中取得与同类口服GLP-1候选药物相竞争的减重数据;Wave Life Sciences的RNA靶向疗法实现了明显的内脏脂肪下降与瘦体重提升;而歌礼制药的ASC30则在美国2期试验中展现出稳定的...
Source Link2025年12月8日,三家企业几乎同时公布的临床结果,让减肥管线的技术版图在一天之内出现了罕见的多点扩展。Structure Therapeutics(硕迪)的口服小分子aleniglipron在2期试验中取得与同类口服GLP-1候选药物相竞争的减重数据;Wave Life Sciences的RNA靶向疗法实现了明显的内脏脂肪下降与瘦体重提升;而歌礼制药的ASC30则在美国2期试验中展现出稳定的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.